Tamoksifen kullanımında kalın endometriumun değerlendirilmesi

Objective & Hypothesis:Objective: Aim of this study was to evaluate role of hysteroscopy in thickened endometrium (>5 mm) associated with tamoxifen therapy.

📊

Key Findings & Data:One hundred and nine asymptomatic patients with estrogen receptor positive breast cancer treated with tamoxifen 20 mg daily.

💡

Conclusion & Impact:J Turk Soc Obstet Gynecol 2014;4:215-8

🔬Design:Research Article

📍Scope:2014 Verileri

⚙️Variables:Domain Parameters

Abstract

Objective: Aim of this study was to evaluate role of hysteroscopy in thickened endometrium (>5 mm) associated with tamoxifen therapy. Materials and Methods: We performed dilatation and curettage (D&C) and hysteroscopic biopsy to patients for evaluation of thickened endometrium in tamoxifen therapy. One hundred and nine asymptomatic patients with estrogen receptor positive breast cancer treated with tamoxifen 20 mg daily. We performed hysteroscopic biopsy or D&C to patients who have thickened endometrium at transvaginal sonography. We correlate pathology report results of D&C and hysteroscopic biopsy. Results: Fifty-nine of 103 patients have thickened endometrium.Thirty-five of 59 patients diagnosed with D&C (19 inactive endometrium, 15 endometrial polyp, 1 endometrial hyperplasia). D&C couldn t get material 24 of these patients. Hysteroscopic biopsy diagnosed endometrial polyp 11 (45.8%) of these patients. Conclusion: We can state that D&C does not seem accurate enough for detection of intrauterin pathologies in thickened endometrium associated with tamoxifen therapy. We therefore believe it is reasonable to perform hysteroscopic biopsy in asymptomatic tamoxifen treated patients who have thickened endometrium. J Turk Soc Obstet Gynecol 2014;4:215-8

Özet

Amaç: Tamoxifen kullanımına bağlı kalınlaşmış endometriumun değerlendirilmesinde histeroskopinin yerini belirlemek. Gereç ve Yöntemler: Tamoxifen kullanımı olan hastalar ilk basamakta trans-vajinal ultrason (TVUS) ile değerlendirildi. Endometrial kalınlaşma (>5 mm) saptanan hastalar histeroskopi ve dilatasyon-küretaja (D&C) yönlendirildi. Çalışmaya östrojen reseptör pozitif meme kanseri olup en az 1 yıldır 20 mg/gün Tanoxifen kullanan 103 hasta üzerinde yapıldı. TVUSda endometrial kalınlaşma (>5 mm) saptanan hastalar histeroskopik biyopsi ve dilatasyon-küretaja yönlendirildi. Endometrial kalınlık saptanan hastaların D&C ve histeroskopik biyopsi sonuçları değerlendirildi. Bulgular: Tamoxifen kullanan 103 hastanın 59 tanesinde endometrial kalınlaşma saptandı. Bu hastaların 35 tanesinde D&Cde materyal elde edilerek patolojik tanı kondu. Materyal elde edilemeyen 24 hasta histeroskopik biyopsiye yönlendirildi. Bu hastaların 11 (%45,8) tanesinde endometrial polip saptandı. Sonuç: Tamoxifen kullanımında endometrial kalınlık saptanan hastalarda D&C tek başına yeterli görünmemektedir. Histeroskopik biyopsi bu hastaların değerlendirilmesinde ilk sırada düşünülmelidir. J Turk Soc Obstet Gynecol 2014;4:215-8

🔖

Cite This Article

TOKGÖZ, V. Y., KORKMAZER, E., SOLAK, N. (2022). Tamoksifen kullanımında kalın endometriumun değerlendirilmesi. Türk Jinekoloji ve Obstetrik Derneği Dergisi, Cilt: 11 - Sayı: 4, 215–218. https://ajindex.com/articles/631492

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (10)

Paschopoulos M, Kontostolis E, Lolis ED, Koliopoulos G, Alamanos Y, Paraskevaidis E. The use of transvaginal sonography and vaginoscopic hysteroscopy in women on tamoxifen. JSLS 2001;5:211-4
Kedar R, Bourne T, Powles T, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-21. 3. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52
Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, van Boven H, et al: Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Res 2012;14:91
Fung MF, Reid A, Faught W, Le T, Chenier C, Verma S, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 2003;91:154-9
Liedman R, Lindahl B, Andolf E, Willen R, Ingvar C, Ranstam J. Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res 2000;20:4889-91
Develioğlu OH, Omak M, Bilgin T, Esmer A, Tüfekçi M. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. Gynecol Oncol 2004;93:328-35
Le Donne M, Lentini M, De Meo L, Benedetto V, Mesiti M. Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings. Eur J Gynaecol Oncol 2005;26:623-6
Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, et al. ATAC Trialists Group: The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. Hum Reprod 2005;20:294-301
No authors listed. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists Collaborative Group. Lancet 1992;339:1-5
Gerber B, Krause A, Muler H, Reimer T, Kulz T, Makovitzky J, et al. Effects of